Bio-Reference Laboratories Announces Strategic Alliance with BD and Introduction of GenFlow.

ELMWOOD PARK, N.J. -- Bio-Reference Laboratories, Inc. (BRLI - NASDAQ), the largest independent regional clinical laboratory in the Northeast, today announced that they have signed a Strategic Marketing Agreement with BDBiosciences, a unit of BD (Becton, Dickinson and Co.) (BDX:NYSE), a global medical technology company. Under the agreement, the companies will work together to develop BRLI's marketing strategies for its GenFlow(R) 'virtual cytometry' solution.

BD assisted BRLI with developing the new BRLI GenFlow(R) product, which allows remote physician customers of BioReference to access the flow cytometry data produced by the BD flow cytometry equipment over the internet to review work product, request changes, additions or modifications and to build reports through the BioReference CareEvolve connectivity portal. The new GenFlow(R) product was introduced on February 18th and will be marketed through the GenPath division of BioReference Laboratories to physicians, hospitals and other healthcare providers throughout the country.

William Rhodes, VP/GM BDBiosciences Cell Analysis, stated, "BioReference has been a long-time user of our flow cytometry solutions, and we were pleased to be able to work with them during the development of GenFlow(R), assuring that the product is compatible with our flow cytometry platforms ,to create what should be a valuable enhancement for their customers. We will continue to work with BioReference in making this solution available to its customers, as well as developing a broader strategic and collaborative agreement with them, particularly in the area of flow cytometry testing for oncology."

Marc D. Grodman, MD, President and CEO of Bio-Reference Laboratories said, "Bio-Reference Laboratories is fully engaged in the clinical diagnosis of hematopathological diseases. Our relationship with BD has been valuable and fruitful in developing what we believe to be the premier diagnostic laboratory for hematological malignancies in the country. Our GenFlow(R) solution will provide practitioners with easy access to their data and will quickly establish our leadership not only as the finest source for medical technology, but as the leading developer of advanced technological solutions that deliver better healthcare through better technology. Over the past year we have invested substantial resources in building an infrastructure that includes the best medical team with the best technical support and the best technology advances in the healthcare marketplace. We have added to that capability the best sales and marketing team armed with the best marketing materials in our industry segment. We thank BD for their contribution to our GenPath division and we look forward to finding other ways that their technology expertise can further help us in the future."

About Bio-Reference Laboratories, Inc.

The Company is the largest independent regional clinical laboratory in the Northeast and has major market positions in physician offices, nursing homes and correctional institutions. The Company is a full service clinical laboratory with specialty capability, especially in the areas of genomics, oncology, correctional health, and complimentary medicine. PSIMedica, a business unit of the Company, is a clinical knowledge management (CKM) organization offering an array of information solutions for reducing healthcare costs and improving quality performance that are based on a flexible, scalable software analytical engine that utilizes all available source information, including claims data, enrollment data, prescription data and laboratory data. The Company provides a comprehensive connectivity solution to physicians, which includes disease management, laboratory reporting and ordering, as well as claims and eligibility processing through CareEvolve, its web-based healthcare portal.

www.bioreference.com

Statements included in this release that are not historical in nature, are intended to be, and are hereby identified as "forward-looking statements". Statements looking forward in time are included in this release pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to be materially different from any future performance suggested herein.